These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 20469674)

  • 21. [Treatment of alcoholic liver diseases. Abstinence, nutritional support, drug therapy, liver transplantation].
    Pár A
    Orv Hetil; 2000 Apr; 141(16):827-33. PubMed ID: 10817009
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of patients with non-alcoholic fatty liver disease: current views and perspectives.
    Federico A; Trappoliere M; Loguercio C
    Dig Liver Dis; 2006 Nov; 38(11):789-801. PubMed ID: 16750661
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Role of metadoxyl in the treatment of the hepatotoxic effects of cytostatics].
    Safonova SA; Gershanovich ML
    Vopr Onkol; 2005; 51(5):599-600. PubMed ID: 16756021
    [No Abstract]   [Full Text] [Related]  

  • 24. Frequency of nonalcoholic steatohepatitis as a cause of advanced liver disease.
    Charlton M; Kasparova P; Weston S; Lindor K; Maor-Kendler Y; Wiesner RH; Rosen CB; Batts KP
    Liver Transpl; 2001 Jul; 7(7):608-14. PubMed ID: 11460228
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Non-alcoholic fatty liver disease/non-alcoholic steatohepatitis (NAFLD/NASH): diagnosis and clinical course.
    Cortez-Pinto H; Camilo ME
    Best Pract Res Clin Gastroenterol; 2004 Dec; 18(6):1089-104. PubMed ID: 15561640
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The ratio of aspartate aminotransferase to alanine aminotransferase: potential value in differentiating nonalcoholic steatohepatitis from alcoholic liver disease.
    Sorbi D; Boynton J; Lindor KD
    Am J Gastroenterol; 1999 Apr; 94(4):1018-22. PubMed ID: 10201476
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Review article: Drug therapy for non-alcoholic fatty liver disease.
    Comar KM; Sterling RK
    Aliment Pharmacol Ther; 2006 Jan; 23(2):207-15. PubMed ID: 16393299
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Beneficial effects of pentoxifylline on hepatic steatosis, fibrosis and necroinflammation in patients with non-alcoholic steatohepatitis.
    Satapathy SK; Sakhuja P; Malhotra V; Sharma BC; Sarin SK
    J Gastroenterol Hepatol; 2007 May; 22(5):634-8. PubMed ID: 17444848
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical and histological features of non-alcoholic fatty liver disease in Hong Kong Chinese.
    Wong VW; Chan HL; Hui AY; Chan KF; Liew CT; Chan FK; Sung JJ
    Aliment Pharmacol Ther; 2004 Jul; 20(1):45-9. PubMed ID: 15225170
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Steatosis and fibrosis: first stage of liver damage induced by chronic alcoholism. Our experience in 100 cases].
    Mancinella A
    Clin Ter; 1991 Apr; 137(1):29-38. PubMed ID: 1828726
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Fatty hepatosis. Non-alcoholic steatohepatitis (evolution of the knowledge about clinico-morphological features, prognosis, treatment)].
    Podymova SD
    Ter Arkh; 2006; 78(4):32-8. PubMed ID: 16821419
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Review article: diagnosis and treatment of non-alcoholic fatty liver disease.
    Oh MK; Winn J; Poordad F
    Aliment Pharmacol Ther; 2008 Sep; 28(5):503-22. PubMed ID: 18532991
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Predictors of fibrosis in Asian patients with non-alcoholic steatohepatitis.
    Tsang SW; Ng WF; Wu BP; Chow DA; Li ET; Wong TC
    J Gastroenterol Hepatol; 2006 Jan; 21(1 Pt 1):116-21. PubMed ID: 16706822
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Serum adipokine levels predictive of liver injury in non-alcoholic fatty liver disease.
    Lemoine M; Ratziu V; Kim M; Maachi M; Wendum D; Paye F; Bastard JP; Poupon R; Housset C; Capeau J; Serfaty L
    Liver Int; 2009 Oct; 29(9):1431-8. PubMed ID: 19422483
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gene expression profile associated with superimposed non-alcoholic fatty liver disease and hepatic fibrosis in patients with chronic hepatitis C.
    Younossi ZM; Afendy A; Stepanova M; Hossain N; Younossi I; Ankrah K; Gramlich T; Baranova A
    Liver Int; 2009 Oct; 29(9):1403-12. PubMed ID: 19515216
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Alcoholic and nonalcoholic steatohepatitis: the same disease! I. Diagnosis and mechanisms].
    Spahr L; Rubbia-Brandt L; Hadengue A
    Rev Med Suisse; 2005 Sep; 1(31):2026-8, 2030-1. PubMed ID: 16212004
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Outcomes of liver transplantation in patients with cirrhosis due to nonalcoholic steatohepatitis versus patients with cirrhosis due to alcoholic liver disease.
    Bhagat V; Mindikoglu AL; Nudo CG; Schiff ER; Tzakis A; Regev A
    Liver Transpl; 2009 Dec; 15(12):1814-20. PubMed ID: 19938128
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Review article: the metabolic syndrome and non-alcoholic fatty liver disease.
    Loria P; Lonardo A; Carulli L; Verrone AM; Ricchi M; Lombardini S; Rudilosso A; Ballestri S; Carulli N
    Aliment Pharmacol Ther; 2005 Nov; 22 Suppl 2():31-6. PubMed ID: 16225469
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: a pilot study.
    Laurin J; Lindor KD; Crippin JS; Gossard A; Gores GJ; Ludwig J; Rakela J; McGill DB
    Hepatology; 1996 Jun; 23(6):1464-7. PubMed ID: 8675165
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Non-alcoholic steatohepatitis].
    Duvnjak M; Virović L
    Acta Med Croatica; 2003; 57(3):189-99. PubMed ID: 14582465
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.